Edition:
India

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.02USD
10:02pm IST
Change (% chg)

$0.01 (+0.99%)
Prev Close
$1.01
Open
$1.02
Day's High
$1.03
Day's Low
$1.01
Volume
6,350
Avg. Vol
168,558
52-wk High
$2.17
52-wk Low
$0.74

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $299.88
Shares Outstanding(Mil.): 147.00
Dividend: --
Yield (%): --

Financials

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update

02 Nov 2017

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

20 Oct 2017

BRIEF-Indivior says ‍durect, co sign $17.5 mln patent purchase deal

* DURECT AND INDIVIOR PLC SIGN A $17.5 MILLION PATENT PURCHASE AGREEMENT​

02 Oct 2017

BRIEF-Durect appoints Myriam Theeuwes as senior vice president of clinical development

* Durect appoints Dr. Myriam Theeuwes as senior vice president, clinical development Source text for Eikon: Further company coverage:

20 Sep 2017

BRIEF-Durect Q2 loss per share $0.07

* Durect Corporation announces second quarter 2017 financial results and provides corporate update

09 Aug 2017

BRIEF-Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

* Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

08 Aug 2017

BRIEF-Zogenix and Durect Corp enter into termination agreement

* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing

03 Aug 2017

BRIEF-Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​

* Durect - ‍on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014​

29 Jul 2017

BRIEF-Durect completes enrollment in persist, phase 3 trial for Posimir

* Durect completes enrollment in Persist, phase 3 trial for Posimir

22 Jun 2017

BRIEF-Durect's collaboration with Sandoz clears HSR review

* Durect's collaboration with Sandoz clears Hart-Scott-Rodino review and is effective

19 Jun 2017

Earnings vs. Estimates